Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir

J Infect Dis. 2002 Jan 15;185(2):162-9. doi: 10.1086/338362. Epub 2001 Dec 17.

Abstract

Most ganciclovir (GCV)-resistant cytomegalovirus (CMV) isolates contain UL97 gene mutations at codon 460 or 520 or between codons 590 and 607, where an increasing variety of mutations have been detected, including deletions. To determine their phenotypic effect, 9 UL97 mutations not previously studied were transferred to drug-sensitive laboratory CMV strains that contained unique restriction sites developed for this purpose. Deletion of the entire codon range 591-607 conferred a 6-fold increase in GCV resistance, with little effect on viral replication. Some mutations found in clinical isolates, including C592G and A594T, conferred only 2-3-fold decreases in GCV susceptibility. For C592G, this phenotype was confirmed by transfer to different CMV strains and by restoration of full drug susceptibility after removal of the mutation. Low drug levels resulting from oral GCV therapy may predispose the virus to the initial selection of these low-grade UL97 resistance mutations and to later accumulation of other mutations and greater resistance.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Sequence
  • Antiviral Agents / pharmacology*
  • Base Sequence
  • Cytomegalovirus / drug effects*
  • Cytomegalovirus / enzymology
  • Cytomegalovirus / genetics
  • Drug Resistance, Viral
  • Ganciclovir / pharmacology*
  • Molecular Sequence Data
  • Mutation*
  • Phosphotransferases (Alcohol Group Acceptor) / genetics*

Substances

  • Antiviral Agents
  • Phosphotransferases (Alcohol Group Acceptor)
  • ganciclovir kinase
  • Ganciclovir